Evidence map›Paper›PMID 29802703›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2018

Amelogenin is a Potential Biomarker for the Aggressiveness in Odontogenic Tumors

Safa Zakaraia, Mamdouh Almohareb, Khaled Zaid, Mazen Doumani, Mohammad Yaman Seirawan

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Safa ZakaraiaDepartment of Oral Histology and Pathology, Faculty of Dentistry, Damascus University, Damascus, Syria.Email: dr.safa.zakarea@gmail.com
Mamdouh Almohareb
Khaled Zaid
Mazen Doumani
Mohammad Yaman Seirawan
Damascus University · SY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amelogenin (AMEL), the major structural protein of the enamel organic matrix, constitutes more than 90% of the enamel’s protein content, Aberrations of amelogenin are thought to be involved in the oncogenesis of odontogenic epithelium. The expression of amelogenin is possibly an indicator of differentiation of epithelial cells in the odontogenic tumors. Aim of the study: Investigating the expression of amelogenin in some odontogenic tumors, using an anti-amelogenin polyclonal antibody, and then compare it with AMEL expression in tooth buds as control. Materials and Methods: study sample consisted of 10 formalin-fixed, paraffin- embedded specimens of ameloblastoma, 10 Keratocystic odontogenic tumors, and 10 tooth buds were conventionally stained with hematoxylin-eosin and immunohistochemically with AMEL polyclonal antibody. Results: All of the odontogenic tumors expressed AMEL in the epithelial component, Intensity of expression in ameloblastoma and Keratocystic odontogenic tumor was lower, compared with tooth buds, Statistical analysis indicated a significant differences between the tumors and tooth buds. Conclusion: Amelogenin can be used as a marker for odontogenic epithelium, and the expression of amelogenin is possibly an indicator of epithelial cells differentiation in the odontogenic tumors, and therefore in prediction of the histological behavior of odontogenic tumors.

Indexed as

AmelogeninBiomarkers, TumorCase-Control StudiesHumansOdontogenic TumorsPrognosisTooth GermAmelogeninBiomarkers, TumorAmeloblastomaAmelogeninKeratocystic odontogenic tumorOncogenesis

Identifiers

PMID29802703
PMCPMC6031836
OpenAlexW2807567781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.